A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989
Status:
Completed
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the single-dose pharmacokinetic (PK) of JNJ-73763976
and JNJ-73763924 following a subcutaneous (SC) injection of JNJ-73763989 (JNJ-3989) in
participants with liver cirrhosis and various degrees of impaired hepatic function when
compared with healthy participants with normal hepatic function and no liver cirrhosis.